[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582391":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":58,"collaborators":10,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":75,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"High VIS Group",null,"High VIS Group: Patients with an average Vasoactive-Inotropic Score (VIS) \\>10 from 12 hours post-ECMO initiation to weaning.",[13],"Other: Vasopressor Exposure Levels",{"label":15,"type":10,"description":16,"interventionNames":17},"Low VIS Group","Low VIS Group: Patients with an average Vasoactive-Inotropic Score (VIS) ≤10 from 12 hours post-ECMO initiation to weaning.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"Vasopressor Exposure Levels","This is an observational study with no active intervention. The study evaluates the association between natural variations in vasopressor exposure levels (measured by Vasoactive-Inotropic Score, VIS) and clinical outcomes in patients receiving VA-ECMO for cardiogenic shock.",[9,15],[24],"Vasoactive-Inotropic Score (VIS)",[26],{"name":27,"affiliation":5,"role":28},"Zhongtao Du, MD","STUDY_CHAIR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Xiaotong Hou, MD","CONTACT","010-64456631","xt.hou@ccmu.edu.cn",{"name":36,"role":32,"phone":37,"phoneExt":10,"email":38},"Chenglong Li, MD","86-18610846901","cl_lee@163.com",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Beijing","Beijing Municipality","100029","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54,56],{"name":27,"role":32,"phone":37,"phoneExt":10,"email":55},"zhongtaodu@126.com",{"name":31,"role":57,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Xiaotong Hou","Clinical professor","100582391","effect-of-reduced-vasopressors-on-mortality-in-ecmo-supported-cardiogenic-shock-patients-100582391",false,"NCT06862700","Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients","Association Between Vasopressor Exposure Levels and 30-Day Mortality in Patients Receiving ECMO Support for Cardiogenic Shock: A Prospective Multicenter Cohort Study","VREM-CS","Inclusion Criteria:\n\n* Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.\n* First-time ECMO initiation.\n* Venoarterial ECMO (VA-ECMO) as the initial mode.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Severe pulmonary hypertension.\n* Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia).\n* Severe missing data.","ALL","18 Years",{"count":73,"type":74},534,"ESTIMATED","30 Days","OBSERVATIONAL","The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is:\n\nDoes reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.",[79,80,81,82,83,84],"Cardiogenic Shock","Extracorporeal Membrane Oxygenation","Vasopressors","Hemodynamic Management","Critical Care","Heart Failure","2025-03-04",{"date":87,"type":88},"2025-03-06","ACTUAL",{"date":90,"type":88},"2025-02-26",{"date":92,"type":74},"2028-01-01",{"name":60,"class":6},1]